Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dubermatinib · TP-0903

Small molecule · Inhibitor of AXL · developed by Sumitomo Pharma America

Phase 2/3 Most advanced trial
1 Registered trials

What is Dubermatinib?

Dubermatinib (TP-0903) is an orally available selective inhibitor of the receptor tyrosine kinase AXL. It blocks AXL-mediated signal transduction and inhibits epithelial-mesenchymal transition, reducing tumor cell proliferation and migration. It is studied in relapsed/refractory acute myeloid leukemia and enhances chemosensitivity to other agents.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TP-0903
Drug type
Small molecule
Targets
AXL
Mechanism
Inhibitor of AXL
Pathways
epithelial-mesenchymal transition (EMT) inhibition, AXL-mediated signal transduction
Therapy area
Hematology
Developer
Sumitomo Pharma America, Inc.
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
14D65TV20J

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on AXL

Mipasetamab Uzoptirine Phase 1 Sitravatinib Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.